Latest Us Army News

Island Pharmaceuticals has expanded its partnership with USAMRIID to conduct a pivotal Galidesivir dose optimisation study against Marburg virus, targeting topline results in the second half of 2026.

Vitrafy Life Sciences has teamed up with Vitalant Innovation Center to tackle the impending gap in red blood cell cryopreservation technology in the US, aiming to replace soon-to-be-discontinued legacy methods and potentially expand into other blood products.

Vitrafy Life Sciences has achieved a major validation milestone with US Army-backed Phase II results showing its no-wash platelet cryopreservation protocol delivers 94% post-thaw recovery, outperforming existing standards and advancing FDA registration plans.

Electro Optic Systems (ASX: EOS) reported a 13% increase in contract backlog to A$518 million in Q1 2026, driven by multiple major defence orders and the opening of a new Singapore facility. The company’s cash position remains strong despite a $4 million ASIC penalty.

Island Pharmaceuticals has cleared a major regulatory hurdle with the US FDA, confirming a clinical development path for its antiviral Galidesivir under the Animal Rule. Backed by a $9 million capital raise and strategic partnerships, the company is poised for potential US government procurement and biodefence market entry.

Anson Resources has lodged an updated Small Mining Operations notice for its 10,000tpa Green River lithium carbonate plant in Utah, marking the last significant regulatory hurdle before construction. The revised plant layout, backed by a near-complete Pre-feasibility Study, leverages existing infrastructure and private land ownership to enhance project bankability.

Electro Optic Systems (ASX: EOS) wraps up a three-year turnaround, reporting a $459 million order backlog despite a 27% revenue drop. The company expands its counter-drone and space control portfolio with the acquisition of the UK-based Interceptor business and a pending deal for MARSS, a European command-and-control software provider.

Electro Optic Systems Holdings Limited (ASX: EOS) has responded to ASX queries confirming that non-executive director Robert Nicholson’s on-market purchase of shares complied with the company’s trading policy and ASX Listing Rules. The trade occurred prior to the public announcement of significant US defence contracts.

Electro Optic Systems secures two significant US contracts worth US$12 million for advanced Remote Weapon Systems, while progressing a conditional US$80 million Korean High Energy Laser contract with potential manufacturing shifts.

Island Pharmaceuticals has entered a pivotal research agreement with USAMRIID and the Geneva Foundation to accelerate FDA approval of Galidesivir for Marburg Virus Disease, leveraging top-tier US biodefense expertise.

IperionX has completed commissioning of its titanium powder and component manufacturing facilities, setting the stage for a major production scale-up backed by US Department of War funding. The company is progressing commercial contracts and advancing its critical minerals project in Tennessee.

Felix Gold has transitioned from exploration to development with a metallurgical breakthrough producing military-grade antimony and is advancing pilot plant operations and government funding applications to meet US military demand.